TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma

Jau Chen Lin, Yi Ying Wu, Jing Yi Wu, Tzu Chieh Lin, Chen Tu Wu, Yih Leong Chang, Yuh Shan Jou, Tse Ming Hong, Pan Chyr Yang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Trop-2, a cell surface glycoprotein, contains both extracellular epidermal growth factor-like and thyroglobulin type-1 repeat domains. Low TROP2 expression was observed in lung adenocarcinoma tissues as compared with their normal counterparts. The lack of expression could be due to either the loss of heterozygosity (LOH) or hypermethylation of the CpG island DNA of TROP2 upstream promoter region as confirmed by bisulphite sequencing and methylation-specific (MS) polymerase chain reaction (PCR). 5-Aza-2′-deoxycytidine treatment on lung cancer cell (CL) lines, CL1-5 and A549, reversed the hypermethylation status and elevated both TROP2 mRNA and protein expression levels. Enforced expression of TROP2 in the lung CL line H1299 reduced AKT as well as ERK activation and suppressed cell proliferation and colony formation. Conversely, silencing TROP2 with shRNA transfection in the less efficiently tumour-forming cell line H322M enhanced AKT activation and increased tumour growth. Trop-2 could attenuate IGF-1R signalling-mediated AKT/β-catenin and ERK activation through a direct binding of IGF1. In conclusion, inactivation of TROP2 due to LOH or by DNA methylation may play an important role in lung cancer tumourigenicity through losing its suppressive effect on IGF-1R signalling and tumour growth.

Original languageEnglish
Pages (from-to)472-485
Number of pages14
JournalEMBO Molecular Medicine
Volume4
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Loss of Heterozygosity
decitabine
Lung Neoplasms
Cell Line
Catenins
CpG Islands
Thyroglobulin
Membrane Glycoproteins
DNA Methylation
Growth
Tumor Cell Line
Epidermal Growth Factor
Genetic Promoter Regions
Methylation
Small Interfering RNA
Transfection
Neoplasms
Cell Proliferation
Polymerase Chain Reaction
Lung

All Science Journal Classification (ASJC) codes

  • Molecular Medicine

Cite this

Lin, Jau Chen ; Wu, Yi Ying ; Wu, Jing Yi ; Lin, Tzu Chieh ; Wu, Chen Tu ; Chang, Yih Leong ; Jou, Yuh Shan ; Hong, Tse Ming ; Yang, Pan Chyr. / TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. In: EMBO Molecular Medicine. 2012 ; Vol. 4, No. 6. pp. 472-485.
@article{fe820cb6990a4219a5a37a3fd1a18254,
title = "TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma",
abstract = "Trop-2, a cell surface glycoprotein, contains both extracellular epidermal growth factor-like and thyroglobulin type-1 repeat domains. Low TROP2 expression was observed in lung adenocarcinoma tissues as compared with their normal counterparts. The lack of expression could be due to either the loss of heterozygosity (LOH) or hypermethylation of the CpG island DNA of TROP2 upstream promoter region as confirmed by bisulphite sequencing and methylation-specific (MS) polymerase chain reaction (PCR). 5-Aza-2′-deoxycytidine treatment on lung cancer cell (CL) lines, CL1-5 and A549, reversed the hypermethylation status and elevated both TROP2 mRNA and protein expression levels. Enforced expression of TROP2 in the lung CL line H1299 reduced AKT as well as ERK activation and suppressed cell proliferation and colony formation. Conversely, silencing TROP2 with shRNA transfection in the less efficiently tumour-forming cell line H322M enhanced AKT activation and increased tumour growth. Trop-2 could attenuate IGF-1R signalling-mediated AKT/β-catenin and ERK activation through a direct binding of IGF1. In conclusion, inactivation of TROP2 due to LOH or by DNA methylation may play an important role in lung cancer tumourigenicity through losing its suppressive effect on IGF-1R signalling and tumour growth.",
author = "Lin, {Jau Chen} and Wu, {Yi Ying} and Wu, {Jing Yi} and Lin, {Tzu Chieh} and Wu, {Chen Tu} and Chang, {Yih Leong} and Jou, {Yuh Shan} and Hong, {Tse Ming} and Yang, {Pan Chyr}",
year = "2012",
month = "6",
day = "1",
doi = "10.1002/emmm.201200222",
language = "English",
volume = "4",
pages = "472--485",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "6",

}

TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. / Lin, Jau Chen; Wu, Yi Ying; Wu, Jing Yi; Lin, Tzu Chieh; Wu, Chen Tu; Chang, Yih Leong; Jou, Yuh Shan; Hong, Tse Ming; Yang, Pan Chyr.

In: EMBO Molecular Medicine, Vol. 4, No. 6, 01.06.2012, p. 472-485.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma

AU - Lin, Jau Chen

AU - Wu, Yi Ying

AU - Wu, Jing Yi

AU - Lin, Tzu Chieh

AU - Wu, Chen Tu

AU - Chang, Yih Leong

AU - Jou, Yuh Shan

AU - Hong, Tse Ming

AU - Yang, Pan Chyr

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Trop-2, a cell surface glycoprotein, contains both extracellular epidermal growth factor-like and thyroglobulin type-1 repeat domains. Low TROP2 expression was observed in lung adenocarcinoma tissues as compared with their normal counterparts. The lack of expression could be due to either the loss of heterozygosity (LOH) or hypermethylation of the CpG island DNA of TROP2 upstream promoter region as confirmed by bisulphite sequencing and methylation-specific (MS) polymerase chain reaction (PCR). 5-Aza-2′-deoxycytidine treatment on lung cancer cell (CL) lines, CL1-5 and A549, reversed the hypermethylation status and elevated both TROP2 mRNA and protein expression levels. Enforced expression of TROP2 in the lung CL line H1299 reduced AKT as well as ERK activation and suppressed cell proliferation and colony formation. Conversely, silencing TROP2 with shRNA transfection in the less efficiently tumour-forming cell line H322M enhanced AKT activation and increased tumour growth. Trop-2 could attenuate IGF-1R signalling-mediated AKT/β-catenin and ERK activation through a direct binding of IGF1. In conclusion, inactivation of TROP2 due to LOH or by DNA methylation may play an important role in lung cancer tumourigenicity through losing its suppressive effect on IGF-1R signalling and tumour growth.

AB - Trop-2, a cell surface glycoprotein, contains both extracellular epidermal growth factor-like and thyroglobulin type-1 repeat domains. Low TROP2 expression was observed in lung adenocarcinoma tissues as compared with their normal counterparts. The lack of expression could be due to either the loss of heterozygosity (LOH) or hypermethylation of the CpG island DNA of TROP2 upstream promoter region as confirmed by bisulphite sequencing and methylation-specific (MS) polymerase chain reaction (PCR). 5-Aza-2′-deoxycytidine treatment on lung cancer cell (CL) lines, CL1-5 and A549, reversed the hypermethylation status and elevated both TROP2 mRNA and protein expression levels. Enforced expression of TROP2 in the lung CL line H1299 reduced AKT as well as ERK activation and suppressed cell proliferation and colony formation. Conversely, silencing TROP2 with shRNA transfection in the less efficiently tumour-forming cell line H322M enhanced AKT activation and increased tumour growth. Trop-2 could attenuate IGF-1R signalling-mediated AKT/β-catenin and ERK activation through a direct binding of IGF1. In conclusion, inactivation of TROP2 due to LOH or by DNA methylation may play an important role in lung cancer tumourigenicity through losing its suppressive effect on IGF-1R signalling and tumour growth.

UR - http://www.scopus.com/inward/record.url?scp=84861872034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861872034&partnerID=8YFLogxK

U2 - 10.1002/emmm.201200222

DO - 10.1002/emmm.201200222

M3 - Article

C2 - 22419550

AN - SCOPUS:84861872034

VL - 4

SP - 472

EP - 485

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 6

ER -